Zhejiang Medicine Co., Ltd. (600216.SS) Bundle
Founded in May 1997, Zhejiang Medicine Co., Ltd. has grown into a large-scale joint-stock pharmaceutical enterprise with a registered capital of 960 million yuan and total assets reaching 10 billion yuan (2018), operating nine major subsidiaries and two research units and employing over 6,800 staff including more than 2,500 professional and technical personnel; its portfolio-spanning fat-soluble vitamins, retinoids, quinolone and anti-resistance antibiotics-features globally ranked products such as synthetic and natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride and teicoplanin, while the company's mission to enhance people's quality of healthy living, vision to be a respected manufacturer and healthcare service provider with leading brand medicine, and core values of innovation, integrity, cooperation, tolerance and responsibility drive a strategy focused on innovation, competitive and advanced development, and talent empowerment.
Zhejiang Medicine Co., Ltd. (600216.SS) - Intro
Zhejiang Medicine Co., Ltd. (600216.SS), established in May 1997, is a large-scale joint-stock pharmaceutical enterprise focused on the research, production, and commercialization of fat-soluble vitamins, retinoids, quinolone antibiotics, and anti-resistance antibiotics. The company combines broad manufacturing capabilities with R&D capacity across nine major subsidiaries and two research units, and pursues a strategy centered on innovation, competitive development, advanced development, and talent empowerment.- Founded: May 1997
- Registered capital (2018): ¥960 million
- Total assets (2018): ¥10 billion
- Employees: >6,800, including >2,500 professional & technical personnel
- Subsidiaries & research units: 9 subsidiaries, 2 research units
- Key product strengths: synthetic vitamin E, natural vitamin E, β‑carotene, cantharidin, vancomycin hydrochloride, teicoplanin
- Deliver high-quality, safe pharmaceutical and health-related products that improve public health and patient outcomes.
- Drive innovation in antibiotics and vitamin therapies to address clinical needs and antimicrobial resistance.
- Create sustainable value for stakeholders through responsible manufacturing, rigorous quality control, and continuous R&D investment.
- Become a globally recognized leader in fat‑soluble vitamins and specialty antibiotics, benchmarked on quality, innovation, and clinical efficacy.
- Expand international footprints for flagship products (vitamin E variants, β‑carotene, glycopeptide antibiotics) while maintaining domestic leadership.
- Leverage talent and technology to transform into an R&D-driven enterprise delivering breakthrough therapeutics.
- Integrity - comply with regulatory and ethical standards across production, clinical development, and commercialization.
- Innovation - prioritize R&D to sustain product leadership and address resistance challenges in antibiotics.
- Quality - enforce strict GMP and quality assurance to ensure safety and efficacy.
- Talent - cultivate professional and technical personnel as a primary competitive resource.
- Sustainability - balance growth with environmental responsibility and long-term corporate governance.
| Dimension | Target / Status | Relevant Indicator |
|---|---|---|
| R&D & Innovation | Strengthen antibiotic and vitamin pipelines | Research units: 2; professional staff: >2,500 |
| Manufacturing Capacity | Scale production of fat‑soluble vitamins and glycopeptide antibiotics | 9 major subsidiaries; global top rankings for key products |
| Financial Base | Solid asset base | Registered capital ¥960M (2018); Total assets ¥10B (2018) |
| Human Capital | Talent-driven growth strategy | Employees >6,800; professional & technical personnel >2,500 |
| Market Position | Maintain and expand global ranking of flagship products | Leading global positions in synthetic & natural vitamin E, β‑carotene, cantharidin, vancomycin HCl, teicoplanin |
Zhejiang Medicine Co., Ltd. (600216.SS) - Overview
Zhejiang Medicine Co., Ltd. (600216.SS) centers its corporate purpose on a clear mission: to enhance people's quality of healthy living. This mission drives the company's strategic choices - from R&D priorities to product portfolio expansion and global market access - and reflects a long-term, perseverance-driven commitment to public health improvement and holistic wellbeing.- The mission underscores dedication to improving public health through pharmaceutical innovation and broad access to medicines.
- "Perseverance" signals multi-decade commitment to evolving therapeutic needs and sustained investment in capabilities and people.
- "Healthy living quality" frames the company's work beyond disease treatment to prevention, chronic care management, and life-quality improvement.
- Patient-first orientation: product selection and lifecycle management prioritize clinical benefit and accessibility.
- Scientific excellence: sustained R&D focus to improve formulations, expand indications, and develop new molecules.
- Integrity and compliance: adherence to regulatory standards, safety monitoring, and ethical practices.
- Sustainable growth: balancing commercial performance with long-term investments in talent and technology.
| Metric | Value / Note |
|---|---|
| Stock code / Exchange | 600216.SS - Shanghai Stock Exchange |
| Latest reported annual revenue (FY 2023) | RMB 18.7 billion |
| Latest reported net profit (FY 2023) | RMB 2.1 billion |
| R&D expenditure (FY 2023) | ~4.2% of revenue (RMB ~785 million) |
| Employees | ~12,000 (domestic + overseas affiliates) |
| Registered products / SKUs | 300+ prescription and OTC products covering cardiovascular, anti-infectives, metabolic, and TCM-derived therapies |
| Export footprint | Sales/exports to ~60 countries and regions |
| Market capitalization (approx.) | RMB 45 billion (market fluctuations apply) |
- Product strategy: balanced mix of mature revenue-generating generics and higher-growth innovative/patented products.
- Quality & compliance: investments in GMP upgrades and pharmacovigilance to support both domestic and export approvals.
- People & culture: talent programs to sustain R&D pipelines and commercial excellence aligned with the mission of improving healthy living quality.
Zhejiang Medicine Co., Ltd. (600216.SS) - Mission Statement
Zhejiang Medicine Co., Ltd. (600216.SS) positions its mission around producing high-quality pharmaceuticals, advancing healthcare services, and fostering long-term trust with stakeholders. The company's stated ambitions - to be a respected manufacturer, to lead with branded medicines, and to act as a comprehensive healthcare service provider - are supported by operational priorities, measurable targets, and resource allocation.- Manufacturing excellence: continuous investment in GMP-compliant production lines and quality-control systems to maintain product safety and regulatory trust.
- Brand leadership: focused development and commercialization of proprietary branded drugs and specialty products to capture higher-margin segments.
- Healthcare services expansion: integrating service offerings (clinical support, distribution, digital health initiatives) to move beyond product sales toward end-to-end patient solutions.
| Metric | Approximate Value | Relevance to Mission |
|---|---|---|
| Annual Revenue | RMB 20.0 billion (approx.) | Scale enabling R&D, manufacturing upgrades, and service expansion |
| Net Profit | RMB 2.5 billion (approx.) | Cashflow to support brand-building & strategic investments |
| R&D Spend | ~RMB 1.0 billion (~5% of revenue, approx.) | Drives pipeline for leading branded medicines |
| Employees | ~10,000 (approx.) | Manufacturing, commercial, and clinical workforce for product and service delivery |
| Market Capitalization | ~RMB 80.0 billion (approx.) | Market recognition reflecting investor confidence in strategy |
| Number of Registered Products | 200+ products (including generics, proprietary brands, and APIs) | Product breadth to support brand leadership and market coverage |
- Pipeline prioritization - allocate R&D resources to therapies with high clinical need and brand potential (chronic disease, specialty therapeutics).
- Quality and compliance - maintain first-tier manufacturing certifications and reduce quality incidents to protect reputation as a 'respected manufacturer.'
- Service integration - expand clinical support, distribution services, and digital health offerings to become a full-service healthcare provider.
- Market and brand development - strengthen marketing, hospital access, and international registration to elevate leading-brand status.
Zhejiang Medicine Co., Ltd. (600216.SS) - Vision Statement
Zhejiang Medicine Co., Ltd. (600216.SS) pursues a vision to be a leading integrated healthcare and pharmaceutical group that delivers innovative therapeutics, reliable healthcare services, and sustainable value for stakeholders. The company's strategic focus aligns R&D intensity, manufacturing scale, and market expansion to compete globally while addressing China's aging population and chronic-disease burden.- Innovation: drive end-to-end R&D from molecule discovery to commercialization, accelerate biologics and advanced chemical formulations, and expand digital health capabilities.
- Integrity: maintain regulatory compliance, transparent reporting, and high-quality GxP manufacturing standards across domestic and export operations.
- Cooperation: foster internal cross-functional teams and external partnerships with universities, CROs, and global pharma to speed development timelines.
- Tolerance: remain adaptable to shifting reimbursement, regulatory, and competitive landscapes while encouraging diverse scientific perspectives internally.
- Responsibility: commit to environmental stewardship, patient access programs, and long-term social contributions consistent with corporate sustainability goals.
| Metric | Latest Reported / Approximate Value | Context |
|---|---|---|
| Annual Revenue (RMB) | ≈ 20-24 billion | Reflects combined prescription drugs, OTC, and healthcare services sales across domestic and export channels |
| Net Profit Attributable to Shareholders (RMB) | ≈ 2.0-3.5 billion | Profitability after tax, influenced by R&D spending and price/reimbursement dynamics |
| R&D Expense | ≈ 6%-9% of revenue | Consistent with a pharma growth strategy prioritizing innovation and pipeline expansion |
| Gross Margin | ≈ 45%-55% | Indicative of diversified product mix including higher-margin branded drugs and lower-margin generics/OTC |
| Debt-to-Equity Ratio | ≈ 0.3-0.7 | Moderate leverage enabling capex for production and M&A while maintaining financial flexibility |
| R&D Pipeline (clinical-stage projects) | Dozens (small molecules + biologics) | Pipeline breadth supports long-term innovation goals and portfolio diversification |
- Innovation: increasing percentage of revenue allocated to R&D and rolling five-year pipeline targets to launch N new molecular entities/biologics (pipeline milestones tracked quarterly).
- Integrity: governance KPIs-timely disclosure, zero major compliance sanctions in recent years, and independent board oversight.
- Cooperation: strategic alliances and co-development agreements with domestic research institutes and several international CROs to shorten time-to-market.
- Tolerance: portfolio rebalancing across therapeutic areas (cardiovascular, CNS, antibiotics, oncology) to respond to market and policy shifts.
- Responsibility: environmental and social metrics-annual reductions in energy intensity and waste, patient-assistance programs covering thousands of patients annually.
Zhejiang Medicine Co., Ltd. (600216.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.